Page 83 - Read Online

Page 10 of 13 Canepa et al. Vessel Plus 2022;6:30 https://dx.doi.org/10.20517/2574-1209.2021.106

investigator-initiated grant from Pfizer and speaker fees from Vifor Pharma. Dr. Scarpa received honoraria
and/or research grant from Alexion, Azafaros, Chiesi, Takeda, Sanofi Genzyme, Ultragenix, Orchard. Other
authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Giovanni B, Gustafson D, Adamson MB, Delgado DH. Hiding in plain sight: cardiac amyloidosis, an emerging epidemic. Can J
Cardiol 2020;36:373-83. DOI PubMed
2. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European
Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 2021;23:512-26. DOI PubMed
3. Witteles RM, Liedtke M. AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management. JACC
CardioOncol 2019;1:117-30. DOI PubMed PMC
4. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail
2019;7:709-16. DOI PubMed
5. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis
research consortium. Adv Ther 2015;32:920-8. DOI PubMed PMC
6. Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time course of common clinical manifestations in patients with transthyretin
cardiac amyloidosis: delay from symptom onset to diagnosis. J Card Fail 2018;24:131-3. DOI PubMed
7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
DOI PubMed
8. Maurer MS, Schwartz JH, Gundapaneni B, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin
amyloid cardiomyopathy. N Engl J Med 2018;379:1007-16. DOI PubMed
9. Kyle RA, Larson DR, Kurtin PJ, et al. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin
Proc 2019;94:465-71. DOI PubMed PMC
10. Zampieri M, Nardi G, Del Monaco G, et al. Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary
Referral Centre in Tuscany. Int J Cardiol 2021;335:123-7. DOI PubMed
11. Tini G, Cappelli F, Biagini E, et al. Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey.
ESC Heart Fail 2021;8:3369-74. DOI PubMed PMC
12. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc
2012;1:e000364. DOI PubMed PMC
13. Gilstrap LG, Dominici F, Wang Y, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-
service Medicare beneficiaries in the United States. Circ Heart Fail 2019;12:e005407. DOI PubMed PMC
14. Tini G, Vianello PF, Gemelli C, Grandis M, Canepa M. Amyloid cardiomyopathy in the rare transthyretin Tyr78Phe mutation. J
Cardiovasc Transl Res 2019;12:514-6. DOI PubMed
15. Dungu JN, Papadopoulou SA, Wykes K, et al. Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR
V122I cardiac amyloidosis. Circ Heart Fail 2016;9:e003352. DOI PubMed
16. López-Sainz Á, de Haro-Del Moral FJ, Dominguez F, et al. Prevalence of cardiac amyloidosis among elderly patients with systolic
heart failure or conduction disorders. Amyloid 2019;26:156-63. DOI PubMed
17. Takeda M, Amano Y, Tachi M, Tani H, Mizuno K, Kumita S. MRI differentiation of cardiomyopathy showing left ventricular
hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart
disease. Jpn J Radiol 2013;31:693-700. DOI PubMed
18. Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and
prevalence of cardiac amyloidosis. JACC Heart Fail 2020;8:712-24. DOI PubMed PMC
19. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type
transthyretin: a prospective, observational cohort study. Circulation 2016;133:282-90. DOI PubMed PMC
20. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with
preserved ejection fraction. Eur Heart J 2015;36:2585-94. DOI PubMed
21. Bennani Smires Y, Victor G, Ribes D, et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart